Market spirits got a boost from Federal Reserve Chair Jerome Powell's comments to Congress on Tuesday, as the Fed chair said ...

People living with an autoimmune disease are nearly twice as likely to suffer from mood problems like depression, anxiety or ...

A handful of prominent companies on Wall Street have seen some Seeking Alpha analyst activity, including both upgrades and downgrades. Among the group is Hims & Hers (NYSE:HIMS) and Shell (NYSE:SHEL), ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

In this week’s edition of InnovationRx, we look at health insurers' vows to improve prior authorization, Bell Labs’ IP ...

Hims & Hers Health HIMS. After $NVO Novo Nordisk abruptly terminated their partnership, citing "deceptive marketing," Hims & Hers fired back with confidence… saying they'll cont ...

US Stock market today saw the Nasdaq leading a tech-powered rally, while the S&P 500 moved closer to record highs, thanks to ...

Tech led US stocks mostly higher on Wednesday, as the S&P 500 kept a bid for record highs in play amid revived hopes for ...

Grindr stands out in the dating app space with 20%+ revenue growth, industry-leading margins, and innovative product ...

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Granted, defense is not a new theme. The Global X Defense Tech ETF SHLD, which has hot plays including Palantir Technologies (PLTR) and Germany's Rheinmetall (XE:RHM), has surged 54% this year. The ...

Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.